Biotechnology from bench to business

• Follow GEN on:
• Login | Register | Subscribe

• ADME/Tox
• Automation
• Bioprocess Scale-Up
• Bioreactors
• Biosimilars
• Cell Culture
• Cell-Based Assays
• Contract Manufacturing
• Gene Therapy
• High-Throughput Screening
• Immunoassay
• Induced Pluripotent Stem Cells
• Informatics
• Liquid Handling
• Protein Characterization
• Protein Detection
• Regenerative Medicine
• RNAi/siRNA
• Stem Cells
• Western Blot

James B. Altman

James B. Altman is a member of the law firm of Miller & Chevalier Chartered. He serves as the coordinator for the firm’s Section 337 practice group, has represented clients in more than 20 Section 337 cases, and is the president of the ITC Trial Lawyers Association.

More GEN Content From This Contributor

Insight & Intelligence™

• Part 1—The U.S. International Trade Commission and Intellectual Property
• Part 2—Tips for Biotech/Pharma Complainants and Respondents When Going to the ITC
• + Show More- Show Less